SwePub
Sök i LIBRIS databas

  Extended search

L773:1878 5492 OR L773:0966 3274
 

Search: L773:1878 5492 OR L773:0966 3274 > Screening of mortal...

Screening of mortality in transplant patients using an assay for immune function

Berglund, David (author)
Uppsala universitet,Transplantationskirurgi
Bengtsson, Mats (author)
Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
Biglarnia, Alireza (author)
Uppsala universitet,Transplantationskirurgi
show more...
Berglund, Erik (author)
Karolinska Institutet,Uppsala universitet,Institutionen för genetik och patologi
Yamamoto, Shinji (author)
Uppsala universitet,Transplantationskirurgi
von Zur-Mühlen, Bengt (author)
Uppsala universitet,Transplantationskirurgi
Lorant, Tomas (author)
Uppsala universitet,Transplantationskirurgi
Tufveson, Gunnar (author)
Uppsala universitet,Transplantationskirurgi
show less...
 (creator_code:org_t)
Elsevier BV, 2011
2011
English.
In: Transplant Immunology. - : Elsevier BV. - 0966-3274 .- 1878-5492. ; 24:4, s. 246-250
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: So far, the ImmuKnow Immune Cell Function Assay (Cylex, Inc., Columbia, MD, USA) has been used to assess risks of infection and rejection in transplant patients. We hypothesized that the ImmuKnow assay might be used for mortality screening in transplant patients overall. METHODS: In the period of February 2007 to December 2009, at the Uppsala University Hospital, 362 patients who received either kidney, kidney+pancreas, kidney+islet cells, liver or liver+kidney allografts were randomly screened using the ImmuKnow assay. All causes of mortality were compared between two groups: patients with at least one ImmuKnow assay below 175ng/mL and patients with all ImmuKnow assays from 175ng/mL and above. Subsequently, the frequency of rejection within thirty days of the ImmuKnow assay was compared between these two groups. RESULTS: The study included 1031 ImmuKnow assays obtained from the 362 patients. A total of 111 patients had at least one ImmuKnow below 175ng/mL and 251 patients had all their ImmuKnow assays from 175ng/mL and above. By January 31st 2010, 16 of 111 patients (14.4%) with at least one ImmuKnow assay below 175ng/mL were deceased, compared to 13 of 251 patients (5.2%) with all ImmuKnow assays from 175ng/mL and above (p=0.0053, Fisher's exact test). There was no difference in the frequency of rejection between the two groups (19.8% versus 17.5%, p=0.66). CONCLUSIONS: In addition to assessing relative risks of infection and rejection in transplant patients, the ImmuKnow assay may be used to identify patients with increased risk of short-term mortality. Transplant patients being highly overimmunosuppressed as assessed by the ImmuKnow assay do not seem to have a lower risk of short-term rejection.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)

Keyword

MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view